Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma.

Science translational medicine - 12 Apr 2023

Zhang Qian, Yang Lucia, Liu Ying Hsiu, Wilkinson John E, Krainer Adrian R

Abstract excerpt

Diffuse midline gliomas (DMGs) are pediatric high-grade brain tumors in the thalamus, midbrain, or pons; the latter subgroup are termed diffuse intrinsic pontine gliomas (DIPG). The brain stem location of these tumors limits the clinical management of DIPG, resulting in poor outcomes for patients. A heterozygous, somatic point mutation in one of two genes coding for the noncanonical histone H3.3 is present in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Oligonucleotides, Antisense
Share to Brain Neoplasms
Share to Cell Differentiation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Glioma

Share to Histones

Source

Open in PubMed Open full text

Identifiers

PMID: 37043556
DOI: 10.1126/scitranslmed.add8280
PMCID: PMC10263181

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma.PMID 37043556Read ↗

Exon-Skipping Antisense Oligonucleotides for H3.3K27M-Altered Diffuse Midline Glioma TherapySemantic proximity Read ↗

H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.Semantic proximity Read ↗

Current Murine Models and New Developments in H3K27M Diffuse Midline GliomasSemantic proximity Read ↗

Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas.Semantic proximity Read ↗

New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline GliomaSemantic proximity Read ↗

Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.Semantic proximity Read ↗

Epigenetic mechanisms and therapeutic advances in diffuse midline glioma (Review).Semantic proximity Read ↗

Oncohistone inhibition reshapes tumor–microenvironment communication in Diffuse Midline Glioma (DMG)Semantic proximity Read ↗

Transcriptomic and epigenetic profiling of ‘diffuse midline gliomas, H3 K27M-mutant’ discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial locationSemantic proximity Read ↗

[Diffuse midline glioma].Semantic proximity Read ↗

Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategiesSemantic proximity Read ↗

Diffuse midline glioma treated with epigenetic agent-based immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.